IpiNovyx Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $10M

  • Investors
  • 9

IpiNovyx General Information

Description

Developer of an immunoproteasome-modulating therapeutics platform designed to transform the treatment of autoimmune and inflammatory diseases. The company's tool helps inhibitors selectively target the immunoproteasome and modulate specific immune cell types, enabling patients to recover from autoimmune and inflammatory diseases and improve their health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 201 East Fifth Street
  • Suite 2505
  • Cincinnati, OH 45202
  • United States
+1 (845)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 201 East Fifth Street
  • Suite 2505
  • Cincinnati, OH 45202
  • United States
+1 (845)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IpiNovyx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A1) 28-Sep-2023 $10M Completed Pre-Clinical Trials
2. Seed Round 05-Oct-2021 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2021 Completed Startup
To view IpiNovyx’s complete valuation and funding history, request access »

IpiNovyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Seed-1
Seed 57,988 $0.000100 $149.84 $149.84 1x $149.84 21.72%
To view IpiNovyx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

IpiNovyx Patents

IpiNovyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165077-A1 Capped dipeptides as proteasome inhibitors Pending 28-Jan-2025

IpiNovyx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IpiNovyx Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Research Bridge Partners Not-For-Profit Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Lilly USA Corporation Minority
Opaleye Hedge Fund Minority
Orange Grove Bio Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

IpiNovyx FAQs

  • When was IpiNovyx founded?

    IpiNovyx was founded in 2021.

  • Where is IpiNovyx headquartered?

    IpiNovyx is headquartered in Cincinnati, OH.

  • What is the size of IpiNovyx?

    IpiNovyx has 5 total employees.

  • What industry is IpiNovyx in?

    IpiNovyx’s primary industry is Drug Discovery.

  • Is IpiNovyx a private or public company?

    IpiNovyx is a Private company.

  • What is the current valuation of IpiNovyx?

    The current valuation of IpiNovyx is .

  • What is IpiNovyx’s current revenue?

    The current revenue for IpiNovyx is .

  • How much funding has IpiNovyx raised over time?

    IpiNovyx has raised $20M.

  • Who are IpiNovyx’s investors?

    Research Bridge Partners, Alexandria Venture Investments, Lilly USA, Opaleye, and Orange Grove Bio are 5 of 9 investors who have invested in IpiNovyx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process